VANCOUVER, Sept. 24 /CNW/ -- CRH Medical Corporation (CRM:TSX-V) announced today that Dr. Bergein F. "Gene" Overholt, one of North America's most distinguished gastroenterologists, has joined its Board of Directors.

Dr. Overholt designed the flexible fiberoptic sigmoidoscope, which subsequently led to development of colonoscopy. His work in outpatient endoscopy led to the development of the first licensed and certified endoscopic ambulatory surgery center in the U.S. He is a former President of both the American Society for Gastrointestinal Endoscopy and the American Society of Outpatient Surgeons.

While maintaining a full clinical practice, Dr. Overholt has participated in the development of new endoscopic treatments and technologies. Dr. Overholt has published more than 100 articles and lectured extensively on gastroenterology. He currently serves as Medical Director of AmSurg Corp (NASDAQ: AMSG) and as President of Gastrointestinal Associates in Knoxville, Tennessee.

"We are honored by Dr. Overholt's support of our efforts to introduce our technology to gastroenterologists throughout the United Sates, allowing them to treat their patients suffering from hemorrhoids. His advice will be invaluable as CRH continues to introduce its CRH O'Regan System(TM) to the profession," stated Chief Executive Officer Edward Wright.

"Having such a renowned clinician and researcher join our Board shows the impact of CRH's Partnership Program on gastroenterologists in the United States and the potential our technology and methodologies can bring to these practices," Wright added.

Commenting on his appointment, Dr. Overholt said, "It is a true honor to serve as a member of the CRH Board of Directors and to participate in shaping the growth of a vibrant company. I look forward to the opportunity." Added Overholt, One of my goals will be to encourage wide spread use of the CRH O'Regan System(TM) as it represents a significant opportunity for all gastroenterologists to improve patient care, satisfaction and quality of life while broadening their practices."

In conjunction with Dr. Overholt's appointment to its Board of Directors the Company has issued Dr. Overholt an option to purchase up to 100,000 common shares in the Company exercisable at a price of CDN$1.65 for a period of 5 years pursuant to its Stock Option Plan.

About CRH Medical Corporation:

CRH Medical Corporation specializes in the treatment of hemorrhoids utilizing its proven treatment protocol and patented proprietary technology. CRH's single use, disposable, hemorrhoid technology is safe and highly effective in treating hemorrhoid grades I - IV. CRH Medical employs two commercialization strategies: First, it operates Centers for Colorectal Health facilities in the United States specializing in the treatment of hemorrhoids and fissures, and colon cancer screening.